Skip to main content
TipRanks
Go Ultimate75% OFF

Foghorn Therapeutics (FHTX) Drug Pipeline

445 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Fhd-609Advanced Synovial SarcomaPhase ITerminatedFHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss TumorsJun 26, 2021―
Decitabine, Fhd-286, Low Dose CytarabineRefractory Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia, Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic LeukemiaPhase IActive Not RecruitingFHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesMay 13, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Foghorn Therapeutics, Inc. (FHTX) have in its pipeline
Foghorn Therapeutics FHTX is currently developing the following drugs: Fhd-609, Decitabine, Fhd-286, Low Dose Cytarabine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.